These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38441601)

  • 41. A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF.
    Rettenbacher M; Andersen AN; Garcia-Velasco JA; Sator M; Barri P; Lindenberg S; van der Ven K; Khalaf Y; Bentin-Ley U; Obruca A; Tews G; Schenk M; Strowitzki T; Narvekar N; Sator K; Imthurn B
    Reprod Biomed Online; 2015 May; 30(5):504-13. PubMed ID: 25735918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical efficacy and efficiency of a 100-IU starting dose of recombinant follicle stimulating hormone (Puregon) in Korean women undergoing in vitro fertilization and embryo transfer.
    Moon SY; Kim SH; Ku SY; Jee BC; Choi YM; Lee JY
    J Obstet Gynaecol Res; 2003 Jun; 29(3):174-9. PubMed ID: 12841702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study.
    Fisch B; Avrech OM; Pinkas H; Neri A; Rufas O; Ovadia J; Loumaye E
    J Assist Reprod Genet; 1995 Jan; 12(1):26-31. PubMed ID: 7580006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A retrospective review comparing the use of Gonal-F and Metrodin-HP for in-vitro fertilisation (IVF).
    Lee C; Mak FS; Keith J; Welsh D; Yapp P; Chin R
    Med J Malaysia; 2003 Mar; 58(1):94-8. PubMed ID: 14556331
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of α and β recombinant FSH (Gonal-F, Puregon) and progesterone upon human endometrial cell proliferation in-vitro: a preliminary study.
    Chang CC; Hsieh YY; Hsu KH; Lin CS
    Gynecol Endocrinol; 2011 Feb; 27(2):110-6. PubMed ID: 20569100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
    Arce JC; Andersen AN; Fernández-Sánchez M; Visnova H; Bosch E; García-Velasco JA; Barri P; de Sutter P; Klein BM; Fauser BC
    Fertil Steril; 2014 Dec; 102(6):1633-40.e5. PubMed ID: 25256937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of letrozole on women with endometriosis undergoing ovarian stimulation for
    Kim SJ; Choo CW; Kim SK; Lee JR; Jee BC; Suh CS; Lee WD; Kim SH
    Gynecol Endocrinol; 2020 Mar; 36(3):257-260. PubMed ID: 31389274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
    Conforti A; Esteves SC; Humaidan P; Longobardi S; D'Hooghe T; Orvieto R; Vaiarelli A; Cimadomo D; Rienzi L; Ubaldi FM; Zullo F; Alviggi C
    Reprod Biol Endocrinol; 2021 Jun; 19(1):91. PubMed ID: 34154604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ovarian Folliculogenesis and Uterine Endometrial Receptivity after Intermittent Vaginal Injection of Recombinant Human Follicle-Stimulating Hormone in Infertile Women Receiving In Vitro Fertilization and in Immature Female Rats.
    Hsu CC; Hsu L; Hsueh YS; Lin CY; Chang HH; Hsu CT
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improving Implantation Rate in 2nd ICSI Cycle through Ovarian Stimulation with FSH and LH in GNRH Antagonist Regimen.
    Setti AS; Braga DPAF; Iaconelli A; Borges E
    Rev Bras Ginecol Obstet; 2021 Oct; 43(10):749-758. PubMed ID: 34784631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.
    Ruvolo G; Bosco L; Pane A; Morici G; Cittadini E; Roccheri MC
    Fertil Steril; 2007 Mar; 87(3):542-6. PubMed ID: 17126339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI.
    Wikland M; Bergh C; Borg K; Hillensjö T; Howles CM; Knutsson A; Nilsson L; Wood M
    Hum Reprod; 2001 Aug; 16(8):1676-81. PubMed ID: 11473962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF.
    Makieva S; Reschini M; Ferrari S; Bonesi F; Polledri E; Fustinoni S; Restelli L; Sarais V; Somigliana E; Viganò P
    Hum Reprod; 2021 Jan; 36(1):130-144. PubMed ID: 33305818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.
    Hoomans EH; Andersen AN; Loft A; Leerentveld RA; van Kamp AA; Zech H
    Hum Reprod; 1999 Oct; 14(10):2442-7. PubMed ID: 10527965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application.
    Wolzt M; Gouya G; Sator M; Hemetsberger T; Irps C; Rettenbacher M; Vcelar B
    Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):259-65. PubMed ID: 25633239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring.
    Wdowiak A; Bojar I
    Reprod Health; 2015 Dec; 12():113. PubMed ID: 26667662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.